Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia

• Published in: The International journal of angiology Vol. 33; no. 4; pp. 318 - 321
• Main Authors: Morales, Luis F., Miyara, Santiago J., Guevara, Sara, Metz, Christine N., Shoaib, Muhammad, Watt, Stacey, Zafeiropoulos, Stefanos, McCann-Molmenti, Alexia, Hayashida, Kei, Takegawa, Ryosuke, Shinozaki, Koichiro, Choudhary, Rishabh C., Brindley, Elena C., Nishikimi, Mitsuaki, Kressel, Adam M., Alsalmay, Yaser M., Mazzotta, Elvio A., Cho, Young Min, Aranalde, Gabriel I., Grande, Daniel A., Zanos, Stavros, Shore-Lesserson, Linda, Becker, Lance B., Molmenti, Ernesto P.
• Format: Journal Article
• Language: English
• Published: 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA Thieme Medical Publishers, Inc 01.12.2024
• Subjects: Rapid Communication
• ISSN: 1061-1711; 1615-5939
• DOI: 10.1055/s-0041-1726366

Abstract We describe the clinical course of a 65-year-old male patient who suffered from hydrocarbon-induced myelodysplasia and was successfully treated with the thrombopoietin receptor agonist (TPO-RA), romiplostim. Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, cytopenias, and increased risk of leukemic transformation. Here, we present a clinical vignette of MDS-associated thrombocytopenia refractory to first-line drugs as well as the TPO-RA, eltrombopag. To date, romiplostim is an U.S. Food and Drug Administration (FDA)-approved drug for idiopathic thrombocytopenic purpura and thrombocytopenia secondary to liver disease. Of note, currently the FDA advises against its use in MDS based on previous long-term safety concerns. Since the therapeutic options for thrombocytopenia in MDS patients are sparse, repurposing and reassessing romiplostim in this setting have been the focus of recent studies. At the time of writing, no published double-blind randomized clinical trials have conducted a head-to-head comparison between romiplostim and eltrombopag in thrombocytopenic MDS patients. To the best of our knowledge, for a thrombocytopenic patient in the setting of MDS, this is the first documented report of refractory clinical response after a 2-year use of eltrombopag in which replacement of treatment with romiplostim resulted in sustained physiological counts of thrombocytes within four weeks.